

## **P-728 - DOES ARIPIRAZOLE DESERVE A SECOND CHANCE IN PARKINSON'S DISEASE PSYCHOSIS?**

P.Michielsen<sup>1</sup>, M.Arts<sup>2</sup>, M.Morrens<sup>3</sup>

<sup>1</sup>GGZ Westelijk Noord Brabant, Halsteren, <sup>2</sup>Elderly Psychiatry, UMCG Groningen, Groningen, The Netherlands, <sup>3</sup>CAPRI, Antwerpen, Belgium

**Introduction:** A case report of a 55 year old male, previously diagnosed with Parkinson's Disease(PD), presenting cognitive deficit and psychotic features on admission, is presented. Aripiprazole, despite not being first choice for this indication, was the only antipsychotic drug to improve psychotic symptoms without worsening motor movement and improving cognitive functioning. A literature review on treatment options in PD psychosis is presented.

**Objectives:** Describe the triad Parkinson's Disease/Cognitive Decline/Psychosis and review treatment options.

**Aims:** To explain the unique activity of aripiprazole in PD Psychosis on the grounds of existing research evidence and neurotransmitter activity.

**Methods:** A case report is described and literature reviewed.

**Results:** Due to its unique receptor binding profile, specifically on 5HTA1 receptors, M1 receptors and its affinity for D2 receptors, aripiprazole seems a promising drug in the treatment of PD psychosis when cognitive decline is equally present. Future prospective studies are needed to test this hypothesis.